Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-Daclizumab + BEAM + ASCT in Hodgkin's Lymphoma
NCT01468311Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Oct 2011
- Primary completion
- Nov 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of yttrium-90 anti-Tac antibody in Hodgkin lymphoma (HL), sponsored by National Cancer Institute. Started Oct 2011; status: terminated.
02
Drugs
yttrium-90 anti-Tac antibody
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01468311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01468311.